| Symbol | INNPF |
|---|---|
| Name | INNOCAN PHARMA CORP. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | T2P 0N7 Canada AB 1015, 926 - 5 Avenue SW |
| Telephone | +972 54-3012842 |
| Fax | — |
| — | |
| Website | https://innocanpharma.com/ |
| Incorporation | CA |
| Incorporated On | 2018 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;OTCQB |
| Auditor | Brightman Almagor & Co.; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | 0001889791 |
| Description | The Corporations business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. Additional info from OTC: Additional info from OTCQB: |
No news found.